Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• ST-segment elevation myocardial infarction (STEMI) triggers significant inflammation, increasing risks of mortality and heart failure (HF).
• Interleukin-1 (IL-1), a key inflammatory mediator, exacerbates myocardial damage post-STEMI.
• RPH-104 targets both alpha and beta isoforms of IL-1, potentially mitigating inflammatory responses.

Purpose of the Study:

• To evaluate the efficacy of RPH-104 in reducing inflammation and adverse outcomes following STEMI.
• To assess the impact of RPH-104 on high-sensitivity C-reactive protein (hsCRP) levels, a marker of inflammation.
• To determine the effect of RPH-104 on heart failure incidence, mortality, and cardiac function.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 102 STEMI patients.
• Participants received a single dose of RPH-104 (80 mg or 160 mg) or placebo.
• Primary endpoint: hsCRP area under the curve (AUC) from day 1 to day 14; secondary endpoints include clinical outcomes and echocardiographic parameters over 12 months.

Main Results:

• The primary endpoint data (hsCRP AUC) is currently being collected.
• Secondary endpoint data collection includes mortality, heart failure hospitalizations, and cardiac function assessments.
• Study completion is anticipated in 2Q 2022, with results pending.

Conclusions:

• The study aims to establish RPH-104 as a novel therapeutic agent for STEMI.
• Findings will elucidate the role of IL-1 inhibition in managing STEMI complications.
• Results are expected to inform future clinical practice for STEMI management.